Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: CureVac

Market Cap 867M 1.01B 798M 749M 1.41B 95.1B 1.42B 9.43B 3.67B 46.57B 3.78B 3.69B 161B P/E Ratio 2026 *
-
P/E Ratio 2027 * -
Enterprise Value 424M 492M 391M 367M 688M 46.53B 696M 4.61B 1.8B 22.78B 1.85B 1.81B 78.96B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-0.21%
6 months-6.80%
Current year+3.10%
Current year 4.48
Extreme 4.48
4.68
1 year 4
Extreme 4.0001
5.58
3 years 2.22
Extreme 2.215
12.36
5 years 2.22
Extreme 2.215
76.22
10 years 2.22
Extreme 2.215
151.8
Manager TitleAgeSince
Chief Executive Officer 56 27/03/2023
Chief Tech/Sci/R&D Officer 60 -
Chief Operating Officer 61 30/06/2021
Director TitleAgeSince
Chairman 75 31/07/2015
Director/Board Member 58 31/07/2015
Director/Board Member 60 31/05/2019

Financials

2026 *2027 *
Net sales - -
Net income -132M -154M -122M -114M -215M -14.53B -217M -1.44B -561M -7.11B -577M -564M -24.65B -
Net Debt - -
Logo CureVac
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Employees
904
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. CVAC Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!